Skip to main content
Top
Published in: Osteoporosis International 10/2019

Open Access 01-10-2019 | Bisphosphonate | Original Article

Bisphosphonates and mortality: confounding in observational studies?

Authors: J. Bergman, A. Nordström, A. Hommel, M. Kivipelto, P. Nordström

Published in: Osteoporosis International | Issue 10/2019

Login to get access

Abstract

Summary

Numerous observational studies suggest that bisphosphonates reduce mortality. This study showed that bisphosphonate use is associated with lower mortality within days of treatment, although the association was not significant until the second week. Such an early association is consistent with confounding, although an early treatment effect cannot be ruled out.

Introduction

The purpose of this study was to examine whether confounding explains why numerous observational studies show that bisphosphonate use is associated with lower mortality. To this end, we examined how soon after treatment initiation a lower mortality rate can be observed. We hypothesized that, due to confounding, the association would be observed immediately.

Methods

This was a retrospective cohort study of hip fracture patients discharged from Swedish hospitals between 1 July 2006 and 31 December 2015. The data covered 260,574 hip fracture patients and were obtained from the Swedish Hip Fracture Register and national registers. Of the 260,574 patients, 49,765 met all eligibility criteria and 10,178 were pair matched (bisphosphonate users to controls) using time-dependent propensity scores. The matching variables were age, sex, diagnoses, prescription medications, type of hip fracture, type of surgical procedure, known or suspected dementia, and physical functioning status.

Results

Over a median follow-up of 2.8 years, 2922 of the 10,178 matched patients died. The mortality rate was 7.9 deaths per 100 person-years in bisphosphonate users and 9.4 deaths in controls, which corresponded to a 15% lower mortality rate in bisphosphonate users (hazard ratio 0.85, 95% confidence interval 0.79–0.91). The risk of death was lower in bisphosphonate users from day 6 of treatment, although the association was not significant until the second week.

Conclusion

Bisphosphonate use was associated with lower mortality within days of treatment initiation. This finding is consistent with confounding, although an early treatment effect cannot be ruled out.
Appendix
Available only for authorised users
Literature
23.
go back to reference Macmahon S, Collins R (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 357:455–462CrossRef Macmahon S, Collins R (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 357:455–462CrossRef
25.
go back to reference Socialstyrelsen (2017) Täckningsgrader 2016. Stockholm [SE] Socialstyrelsen (2017) Täckningsgrader 2016. Stockholm [SE]
44.
go back to reference Socialstyrelsen (2014) Nationella riktlinjer – utvärdering: vård vid rörelseorganens sjukdomar 2014: indikatorer och underlag för bedömningar. Stockholm [SE] Socialstyrelsen (2014) Nationella riktlinjer – utvärdering: vård vid rörelseorganens sjukdomar 2014: indikatorer och underlag för bedömningar. Stockholm [SE]
Metadata
Title
Bisphosphonates and mortality: confounding in observational studies?
Authors
J. Bergman
A. Nordström
A. Hommel
M. Kivipelto
P. Nordström
Publication date
01-10-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 10/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-05097-1

Other articles of this Issue 10/2019

Osteoporosis International 10/2019 Go to the issue